Tue05212024

Last updateTue, 30 Apr 2024 4pm

Back You are here: Inicio Biology & biomedicine Success stories New biomimetic skin gels patents, developed at IQAC-CSIC, are acquired by Bicosome

New biomimetic skin gels patents, developed at IQAC-CSIC, are acquired by Bicosome

Two new patents developed at the Institute of Advanced Chemistry of Catalonia (IQAC) from the CSIC have been licensed by Bicosome company. The new technological platforms made of only lipids and water do not need the presence of polymers, surfactants, or other gelling agents, bringing valuable benefits for skin care, especially sensitive skin.


The collaboration between Bicosome and IQAC is long term and focused on generating natural, sustainable, and environmentally friendly solutions for skin care. Their first collaboration gave rise to the Bicosome dual delivery systems patent, a nanostructured technology that mimics the lamellar bodies transportation function into target skin layers. This patent generated most products within the current Bicosome portfolio.

The new lipid gel patents are complementary to Biosome’s current IP for skin delivery. Dra Olga Lopez, the leader of the invention and Scientist at IQAC – CSIC stated “The biomimetic gels have a unique organization, with part of the water being trapped in a framework of lipid structures. This makes them ample to transport actives of a different nature due to the actives being in different compartments.”

“The structure and fluidity of the biomimetic gels respond in a reversible way to temperature and pH and their rheological behaviour makes them easy to apply topically."

According to Bicosome Technical Director, Dra Gelen Rodriguez “The structure and fluidity of the biomimetic gels respond in a reversible way to temperature and pH and their rheological behaviour makes them easy to apply topically. They will be able to be used at a surface level as a cutaneous acid mantle substitute, protecting the skin as well as acting as a reservoir for target molecules.”


The gels exclusive hydrolipidic composition guarantees a high biocompatibility and its capacity to respond to biological parameters points to promising applications in future products. According to Bicosome CEO Dra Lucyanna Barros “these new technologies are perfectly in line with the company’s mission to create innovative technologies mimicking skin functions in order to provide customers with sophisticated nature driven skin delivery solutions.”

Bicosome estimates that the first products with this new technology will be fully available for customers in two years.

Bicosome Company develops and commercializes advanced skincare ingredients based on a patented proprietary platform, the Bicosome® technology. Bicosome Company was created in the IQAC-CSIC, by a group of scientists who specialized in the study of the skin tissue. The company mission is to develop biomimetic skincare technologies to produce highly effective science-based products.